1080603-07-1

Basic information

• Product Name: 3,5-dibromo-N-methoxy-N-methyl-benzamide
• Synonyms: 3,5-dibromo-N-methoxy-N-methyl-benzamide
• CAS NO: 1080603-07-1
• Molecular Weight: 322.984
• Mol File: 1080603-07-1.mol

Chemical Properties

• CAS DataBase Reference: 3,5-dibromo-N-methoxy-N-methyl-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dibromo-N-methoxy-N-methyl-benzamide(1080603-07-1)
• EPA Substance Registry System: 3,5-dibromo-N-methoxy-N-methyl-benzamide(1080603-07-1)

Safety Data

• Hazardous Substances Data: 1080603-07-1(Hazardous Substances Data)

Upstream product

• 23950-59-6 3,5-dibromobenzoyl chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 618-58-6 3,5-dibromobenzoic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 14401-73-1 3,5-dibromoacetophenone 
• 1080603-09-3 4-(3,5-dibromophenyl)pyrimidin-2-ylamine 
• 1561965-21-6 ethyl 5-(cyclohexylmethyl)-1-(3-(2-hydroxypropan-2-yl)-5-(1-methylcyclopropyl)phenyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate 
• 1561965-18-1 ethyl 1-(3-(2-(benzyloxy)propan-2-yl)-5-(1-methylcyclopropyl)phenyl)-5-(cyclohexylmethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate 
• 1561965-15-8 ethyl 1-(3-(2-(benzyloxy)propan-2-yl)-5-(1-methylcyclopropyl)phenyl)-5-(cyclohexyl(hydroxy)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylate 
• 1561965-14-7 C₃₀H₃₅NO₄ 
• 1561965-11-4 1-(2-(benzyloxy)propan-2-yl)-3-bromo-5-(1-methylcyclopropyl)benzene 
• 1403387-71-2 1-bromo-3-(2-methoxypropan-2-yl)-5-(1-methylcyclopropyl)benzene 
• 1403387-70-1 2-(3-bromo-5-(1-methylcyclopropyl)phenyl)propan-2-ol 
• 1403387-72-3 1,3-dibromo-5-(1-methylcyclopropyl)benzene 

Relevant articles and documents

Janus-type dendritic organoiridium (III) complex bearing holeand electron-transporting moieties: Synthesis, luminescence properties, and OLED applications

A novel tris-cyclometalated iridium(III) complex bearing carbazole-based hole-transporting and triarylphosphine oxidebased electron-transporting dendrons was synthesized through a convergent synthetic route, and its facial and meridional isomers were isol

HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES

The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS

This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful.

Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L

The magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic ca

SHMT INHIBITORS

The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMTl and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

PYRAZOLOPYRANS HAVING HERBICIDAL AND PHARMACEUTICAL PROPERTIES

The present invention relates to a pyrazolopyran of the general formula I wherein the variables are defined according to the description, including a tautomer, salt, cleavable prodrug, or mixtures thereof, in particular to said pyrazolopyran for use as a medicament and/or an inhibitor of the enzyme serinehydroxymethyltransferase (SHMT). The invention also relates to a process the preparation of a pyrazolopyran of the formula I, to compositions comprising said compound and processes for the preparation of these compositions. Further it relates to use of the pyrazolopyran of formula I as an herbicide as well as to a method of controlling undesired vegetation.

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.